The different stages of visual recognition need different attentional binding strategies von Tsotsos, John K, Rodríguez-Sánchez, Antonio J, Rothenstein, Albert L, Simine, Eugene

Volltext

Towards a Biologically Plausible Active Visual Search Model von Zaharescu, Andrei, Rothenstein, Albert L., Tsotsos, John K.

Volltext

TarzaNN : A General Purpose Neural Network Simulator for Visual Attention Modeling von Rothenstein, Albert L., Zaharescu, Andrei, Tsotsos, John K.

Volltext

Watching the uniformly accelerated reference frame von Rothenstein, B F, Rothenstein, A L

Volltext

Attentional modulation and selection--an integrated approach von Rothenstein, Albert L, Tsotsos, John K

Volltext

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC von Socinski, Mark A, Jotte, Robert M, Cappuzzo, Federico, Orlandi, Francisco, Stroyakovskiy, Daniil, Nogami, Naoyuki, Rodríguez-Abreu, Delvys, Moro-Sibilot, Denis, Thomas, Christian A, Barlesi, Fabrice, Finley, Gene, Kelsch, Claudia, Lee, Anthony, Coleman, Shelley, Deng, Yu, Shen, Yijing, Kowanetz, Marcin, Lopez-Chavez, Ariel, Sandler, Alan, Reck, Martin

Volltext

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC von Antonia, Scott J, Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Hui, Rina, Kurata, Takayasu, Chiappori, Alberto, Lee, Ki H, de Wit, Maike, Cho, Byoung C, Bourhaba, Maryam, Quantin, Xavier, Tokito, Takaaki, Mekhail, Tarek, Planchard, David, Kim, Young-Chul, Karapetis, Christos S, Hiret, Sandrine, Ostoros, Gyula, Kubota, Kaoru, Gray, Jhanelle E, Paz-Ares, Luis, de Castro Carpeño, Javier, Faivre-Finn, Corinne, Reck, Martin, Vansteenkiste, Johan, Spigel, David R, Wadsworth, Catherine, Melillo, Giovanni, Taboada, Maria, Dennis, Phillip A, Özgüroğlu, Mustafa

Volltext

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer von Antonia, Scott J, Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Hui, Rina, Yokoi, Takashi, Chiappori, Alberto, Lee, Ki H, de Wit, Maike, Cho, Byoung C, Bourhaba, Maryam, Quantin, Xavier, Tokito, Takaaki, Mekhail, Tarek, Planchard, David, Kim, Young-Chul, Karapetis, Christos S, Hiret, Sandrine, Ostoros, Gyula, Kubota, Kaoru, Gray, Jhanelle E, Paz-Ares, Luis, de Castro Carpeño, Javier, Wadsworth, Catherine, Melillo, Giovanni, Jiang, Haiyi, Huang, Yifan, Dennis, Phillip A, Özgüroğlu, Mustafa

Volltext

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH) von Peters, Solange, Gettinger, Scott, Johnson, Melissa L, Jänne, Pasi A, Garassino, Marina C, Christoph, Daniel, Toh, Chee Keong, Rizvi, Naiyer A, Chaft, Jamie E, Carcereny Costa, Enric, Patel, Jyoti D, Chow, Laura Q M, Koczywas, Marianna, Ho, Cheryl, Früh, Martin, van den Heuvel, Michel, Rothenstein, Jeffrey, Reck, Martin, Paz-Ares, Luis, Shepherd, Frances A, Kurata, Takayasu, Li, Zhengrong, Qiu, Jiaheng, Kowanetz, Marcin, Mocci, Simonetta, Shankar, Geetha, Sandler, Alan, Felip, Enriqueta

Volltext

A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer von Fung, A.S., Graham, D.M., Chen, E.X., Stockley, T.L., Zhang, T., Le, L.W., Albaba, H., Pisters, K.M., Bradbury, P.A., Trinkaus, M., Chan, M., Arif, S., Zurawska, U., Rothenstein, J., Zawisza, D., Effendi, S., Gill, S., Sawczak, M., Law, J.H., Leighl, N.B.

Volltext

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progr... von Moore, M., Gill, S., Asmis, T., Berry, S., Burkes, R., Zbuk, K., Alcindor, T., Jeyakumar, A., Chan, T., Rao, S., Spratlin, J., Tang, P.A., Rothenstein, J., Chan, E., Bendell, J., Kudrik, F., Kauh, J., Tang, S., Gao, L., Kambhampati, S.R.P., Nasroulah, F., Yang, L., Ramdas, N., Binder, P., Strevel, E.

Volltext

IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev i... von Reck, M., Wehler, T., Orlandi, F., Nogami, N., Barone, C., Moro-Sibilot, D., Shtivelband, M., González Larriba, J.L., Rothenstein, J., Frueh, M., Shankar, G., Lee, A., Deng, Y., Patel, H., Kelsch, C., Lin, W., Socinski, M.A.

Volltext

Attention links sensing to recognition von Rothenstein, Albert L., Tsotsos, John K.

Volltext

Generation of luminescence in biomineralized zirconia by zirconia-binding peptides von Rothenstein, D, Shopova-Gospodinova, D, Bakradze, G, Jeurgens, L. P. H, Bill, J

Volltext

Exposure data for cosmetic products: lipstick, body lotion, and face cream von Loretz, L.J., Api, A.M., Barraj, L.M., Burdick, J., Dressler, W.E., Gettings, S.D., Han Hsu, H., Pan, Y.H.L., Re, T.A., Renskers, K.J., Rothenstein, A., Scrafford, C.G., Sewall, C.

Volltext

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiv... von Bradbury, Penelope A., Morris, Donald G., Nicholas, Garth, Tu, Dongsheng, Tehfe, Moustapha, Goffin, John R., Shepherd, Frances A., Gregg, Richard W., Rothenstein, Jeffrey, Lee, Christoper, Kuruvilla, Sara, Keith, Bruce D., Torri, Vamsee, Blais, Normand, Hao, Desiree, Korpanty, Grzegorz J., Goss, Glenwood, Melosky, Barbara L., Mates, Mihaela, Leighl, Natasha, Ayoub, Jean-Pierre, Sederias, Joana, Feilotter, Harriet, Seymour, Lesley, Laurie, Scott A.

Volltext

1386PDIMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo +... von Reck, M, Wehler, T, Orlandi, F, Nogami, N, Barone, C, Moro-Sibilot, D, Shtivelband, M, González Larriba, J L, Rothenstein, J, Frueh, M, Shankar, G, Lee, A, Deng, Y, Patel, H, Kelsch, C, Lin, W, Socinski, M A

Volltext

Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: A propensity score analysis von Dasgupta, Tina, Rothenstein, Diana, Chou, Joanne F, Zhang, Zhigang, Wright, Jean L, Saltz, Leonard B, Temple, Larissa K, Paty, Philip B, Weiser, Martin R, Guillem, Jose G, Nash, Garrett M, Goodman, Karyn A

Volltext

Real-world evidence on treatment patterns and survival among ALK+ NSCLC patients in Canada who discontinue crizotinib treatment von Kayaniyil, Sheena, Hurry, Manjusha, Wilson, John, Wheatley-Price, Paul, Melosky, Barbara L., Rothenstein, Jeffrey, Cohen, Victor, Koch, Caroline, Zhang, Jie, Osenenko, Katherine, Liu, Geoffrey

Volltext

Patients’ willingness to pay for blood-based EGFR T790M testing: Results from a Canadian validation study of circulating DNA T790M testing von Barnes, Tristan Alexandra, Laskin, Janessa J., Cheema, Parneet Kaur, Liu, Geoffrey, Iqbal, Mussawar, Rothenstein, Jeffrey, Burkes, Ronald L., Owen, Scott Peter, Laurence, David, Carvalhana, Ilda, Markin, Leslie, Wong, Linda, Perera-Low, Nicole, Sawczak, Magdalena, Tsao, Ming-Sound, Leighl, Natasha B.

Volltext